Global Information
회사소개 | 문의 | 위시리스트

CIAS(Cognitive Impairment Associated With Schizophrenia) : 파이프라인 리뷰

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 255980
페이지 정보 영문 84 Pages
가격
US $ 2,000 ₩ 2,308,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,616,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,924,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


CIAS(Cognitive Impairment Associated With Schizophrenia) : 파이프라인 리뷰 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 84 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

정신분열증 환자의 경우 인지 기능의 경도-중도 장애를 볼 수 있습니다. 주요 증상으로서 실행 기능 약화, 집중력 유지의 어려움, 워킹메모리(작업 기억)에 관한 문제 등을 들 수 있습니다. 소인이 되는 요소로서 가족력, 연령, 자가면역질환 등을 들 수 있습니다. 주요 치료법으로서 항정신병약 투여 등이 있습니다.

세계 각국의 CIAS(Cognitive Impairment Associated With Schizophrenia) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 치료제 개요, 최신 업계 동향 등의 조사 결과를 전해드립니다.

목차

서론

  • 분석 범위

CIAS(Cognitive Impairment Associated With Schizophrenia) 개요

치료제 개발

  • CIAS용 파이프라인 제품 : 개요
  • CIAS용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 CIAS 치료제

파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품
  • 불명확한 단계 제품

CIAS 치료제 : 개발중인 제품 목록(기업별)

CIAS 치료제 개발에 참여하고 있는 기업

  • AbbVie Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Astellas Pharma Inc.
  • Avineuro Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Iproteos S.L.
  • Mnemosyne Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • Pfizer Inc.
  • Saniona AB
  • Siena Biotech S.p.A.
  • SK Biopharmaceuticals Co., Ltd.
  • Sunovion Pharmaceuticals Inc. 36
  • Takeda Pharmaceutical Company Limited
  • Upsher-Smith Laboratories, Inc.
  • Vanda Pharmaceuticals Inc.

CIAS : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

치료제 개요

  • A-431404
    • 제품 개요
    • 작용기서(MoA)
    • 연구 개발(R&D) 진전 상황
  • AN-761
  • AQW-051
  • ASP-4345
  • ASP-5736
  • AUT-1
  • AUT-6
  • AUT-9
  • AVL-3288
  • AVN-211
  • DSP-3748
  • eltoprazine
  • encenicline hydrochloride
  • erteberel
  • IC-041
  • IPR-001
  • IPR-088
  • IPR-19
  • ITI-214
  • LUAF-64280
  • NSI-189
  • PF-04958242
  • PNU-120596
  • roflumilast
  • SEN-15924
  • SKL-15508
  • SKL-A4R
  • Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System
  • Small Molecules for Cognitive Impairment Associated with Schizophrenia
  • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia
  • Small Molecules to Agonize NMDA2B for CIAS
  • TAK-058
  • TAK-915

CIAS 치료제 : 최신 치료제 개요

CIAS 치료제 : 개발이 휴지 상태인 제품

CIAS 치료제 : 개발이 중지된 제품

CIAS 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향과 프레스 릴리스(총 6건)

부록

도표

KSM 15.11.24

List of Tables

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim GmbH, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Co, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sosei Heptares, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 5, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Biogen Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Co
    • Cadent Therapeutics Inc
    • Coronis NeuroSciences Ltd
    • Eli Lilly and Co
    • F. Hoffmann-La Roche Ltd
    • Iproteos SL
    • Pfizer Inc
    • SK Biopharmaceuticals Co Ltd
    • Sosei Heptares
    • Spherium Biomed SL
    • Takeda Pharmaceutical Co Ltd
    • Vanda Pharmaceuticals Inc
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles
    • ASP-4345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-5736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-3288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basmisanil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-425809 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIIB-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-955829 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAD-8688 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erteberel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-9936 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPR-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSN-2814617 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-03463275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-20540 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-14040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVND-4010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVNG-3031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-831 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VQW-765 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0467154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a "RETOS-Colaboracion" grant
      • Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
      • Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q
 
BCC Research